Abstract
Abstract
Introduction
Miscarriage occurs in 15%–20% of clinically recognised pregnancies. It may cause acute or prolonged psychological distress such as anxiety, depression and post-traumatic stress disorder (PTSD). Data on symptom severity and duration after miscarriage are limited. This study assesses the prevalence, severity, risk and protective factors of acute and prolonged psychological symptoms as well as the impact of prolonged distress on future general and reproductive health.
Methods and analysis
This prospective observational cohort study enrols patients and partners at the time of miscarriage diagnosis. As controls, we enrol patients with spontaneous or assisted reproductive technology (ART)-conceived ongoing pregnancies and patients requesting induced abortion. Participants complete validated questionnaires within 1 week after enrolment, and at 3 and 9 months. The primary objective is to study the prevalence and severity of acute and prolonged psychological symptoms, including anxiety, depression and PTSD, to determine the need for psychological support. Secondary objectives include studying the effects of patient characteristics, socioeconomic background and previous physical and psychiatric health on symptom persistence and possible effects on subsequent pregnancies. Information is collected both through prospective self-reported questionnaires and retrospectively through national registries. A voluntary blood sample at enrolment is collected to search for endocrine, metabolic, inflammatory and genetic markers involved in miscarriage and psychiatric morbidity. Based on power calculations we plan to enrol 439 patients in the miscarriage and ongoing pregnancy groups and 220 patients in the induced abortion and ART groups. Partners are invited to participate.
Ethics and dissemination
The study will be performed in accordance with ethical principles consistent with the Declaration of Helsinki, ICH/GCPE6 (R2), European Union Clinical Trials Directive and applicable local regulatory requirements. The study has received approval from the ethics committee of the Helsinki University Hospital and from the Helsinki University Hospital. A collaborative agreement with the Helsinki Biobank has been made for depositing blood samples. The results of this study will be disseminated via publication in peer-reviewed journals.
Keywords: GYNAECOLOGY, Reproductive medicine, Anxiety disorders, Depression & mood disorders, Pregnant Women
STRENGTHS AND LIMITATIONS OF THIS STUDY.
Rigorous demographic, medical and follow-up data are available as patients are recruited and followed within the Helsinki University Hospital.
Sociodemographic and economic information, information on past and future psychiatric morbidity and reproductive health is available through national registries.
Biobanked blood samples offer a possibility to search for endocrine, metabolic, inflammatory and genetic markers involved in miscarriage and psychiatric morbidity.
Questionnaires are only available in Finnish and Swedish, excluding participants who cannot communicate using these languages.
Sociodemographic and economic background may affect the willingness to participate, thus affecting the representativeness of the cohort on a population level.
Introduction
Approximately 15%–20% of clinically recognised pregnancies result in miscarriage and altogether 25% of all women experience a miscarriage during their reproductive lifespan.1–3 The medical management of miscarriage is routine and straightforward, mostly involving either expectant or medication-based management (90%) while some 10% are managed surgically.4 Most miscarriages occur during the first trimester of pregnancy and complications or prolonged need for treatment arise in less than 5% of cases regardless of treatment modality. Nevertheless, many patients report dissatisfaction with miscarriage care and call for more compassionate, individualised and patient-centred care, including clear information, emotional support, shared decision-making and appropriate follow-up.5 6
Many experience profound grief and symptoms of psychological distress following miscarriage. Acute stress reactions and symptoms of anxiety and depression are common responses to pregnancy loss, which often decrease in frequency and intensity over time.7 8 Clinically significant symptoms of anxiety have been reported in 29% of patients shortly after miscarriage and in 17% at 9 months while symptoms of depression have been reported in 15% shortly after miscarriage and in 6% at 9 months.9 Symptoms consistent with post-traumatic stress disorder (PTSD) have been reported in up to 29% of patients at the time of miscarriage diagnosis and in 18% 9 months later.9 10 These findings indicate that the psychological effects of miscarriage can be substantial and persistent, highlighting the importance of identifying the patients in need of psychosocial support and providing appropriate service and follow-up.
Several risk factors of psychological morbidity following miscarriage have been identified. Not having living children, a history of infertility or miscarriage, later gestational age at the time of pregnancy loss and having previously seen a viable fetus on ultrasound have been associated with an increased risk of depressive symptoms.11 12 Previous or current psychiatric morbidity, lower levels of partner support or relationship satisfaction have also been associated with risk of anxiety and depression after miscarriage.13 A history of pregnancy loss (miscarriage, termination of pregnancy for fetal anomaly, stillbirth and neonatal death) may further increase the risk of anxiety, depression and stress following a subsequent loss.14–16 In contrast, older age, previous live births and social support can protect against depression after miscarriage.17
Here we report the design and protocol of a Psychological STress, Anxiety, and Depression After miscarriage in comparison to successful pregnancy and abortion-study (STRADA). The study aims to expand the existing evidence by comparing the prevalence, severity and persistence of psychological symptoms following miscarriage to other pregnancy outcomes. The study also aims to identify risk and resilience factors—both sociodemographic and biological—associated with severe or persistent psychological symptoms following miscarriage. Our findings may inform design of tools to identify individuals at risk of severe or persistent psychological symptoms or psychiatric morbidity following miscarriage who may benefit from timely preventive interventions.
Methods and analysis
Design
The STRADA study is a prospective observational cohort study primarily designed to compare the prevalence, severity and persistence of psychological symptoms related to miscarriage, spontaneous ongoing pregnancy, induced abortion and pregnancies conceived through assisted reproductive technology (ART). Eligible patients and partners are enrolled at or shortly after early pregnancy related visits, with the aim to assess symptoms within a week after the pregnancy outcome or study enrolment and at 3-month and 9-month follow-up using validated questionnaires measuring psychological burden as well as resilience. We will also analyse prospective self-reported data on social support, positivity, resilience and domestic violence and data from national registries on sociodemographic, social and socioeconomic status as well at purchases of psychotropic medications. Self-reported lifestyle factors, including level of physical activity, nutrition, smoking status and alcohol consumption, are mapped at each timepoint. Recruitment started in April 2024 and is currently ongoing.
Study population and recruitment
All participants are recruited at the department of obstetrics and gynaecology of the Helsinki University Hospital responsible for specialist healthcare in the Helsinki Metropolitan area. Planned recruitment as well as inclusion and exclusion criteria are displayed in figure 1.
Figure 1. ART, assisted reproductive technology; STRADA, Psychological STress, Anxiety, and Depression After miscarriage in comparison to successful pregnancy and abortion-study.

The study group consists of women diagnosed with miscarriage, defined as non-viable intrauterine pregnancy below 22+0 weeks of gestation and classified as either spontaneous miscarriage, anembryonic pregnancy or missed abortion. The miscarriage diagnosis is based on commonly approved clinical and ultrasonographic findings.4 Pregnancies can be either spontaneous or conceived through ART.
Women participating in routine first trimester fetal screening and found to have a viable spontaneous or ART-conceived singleton pregnancy as well as women requesting an induced abortion are recruited as comparison groups.
Inclusion criteria include a minimum age of 18 years and sufficient knowledge in either of the native languages, Finnish or Swedish, to be able to sign an electronic informed consent and to fill in validated questionnaires on psychological well-being online. Partners are invited to participate. Women with past or current psychiatric morbidity requiring follow-up in specialised psychiatric care are excluded. Past mild depression or anxiety without the need for current follow-up are not reasons prompting exclusion.
The study group will be enrolled at the time of miscarriage diagnosis, with the aim of having them start the study within 1 week of diagnosis. Miscarriage treatment follows national and international guidelines and is currently mainly medical, that is, a combination of mifepristone and misoprostol.4 18
Participants in the comparison groups are recruited at or shortly after routine visits. Women with a spontaneous pregnancy are approached after verification of a viable pregnancy at their first trimester screening ultrasonography conducted at a gestational age between 84–94 days (12+0 to 13+3 weeks). Those consenting but later diagnosed with a fetal malformation, genetic disorder or intrauterine fetal death above gestational age 153 days (≥22+0 weeks) will be excluded.
Women conceiving after ART are approached in connection with ultrasonography to confirm fetal viability at 49–56 days (7+0 to 8+0 weeks) of gestation or at their first trimester screening ultrasonography. Some of these women are likely to be subsequently diagnosed with a miscarriage, in which case they are invited to participate in the miscarriage arm of the study.
Women requesting an induced abortion are approached at the time of assessment at the clinic. Abortion is available on social grounds until gestational age 140 days (20+0 weeks), but most women request abortion in early first trimester. Abortion care follows national and international guidelines and is identical to miscarriage care.19
Information concerning the study is also displayed on digital screens at recruiting clinics and through social media platforms. The study website (stradatutkimus.fi) invites those interested in participating to sign up for eligibility evaluation.
Sample size
The sample size is based on prior reports on the prevalence of prolonged psychological symptoms after miscarriage, namely that psychological symptoms, including PTSD, anxiety and depression, occur in approximately 17% at 9 months post-miscarriage (2–4), while 10% experience symptoms meeting the same criteria during an ongoing spontaneous pregnancy.11
Using a two-sided test, an alpha error of 5% and a beta error of 20%, and accounting for a 15% drop-out rate after informed consent, 439 patients in the two main comparison groups are needed to detect clinically significant differences in psychological outcomes.20 Women seeking induced abortion and women conceiving through ART will be included as smaller groups, collected at a ratio of 1:0.5 (220 in each group), as the hospital sees these groups in fewer numbers.
Data collection and measures
Questionnaires
At enrolment, participants are asked to fill in information concerning their background, including level of education, occupation and working status, marital or relationship status as well as current and past health problems. Information about whether the pregnancy was planned or unplanned is also collected.
Questionnaires measuring psychological symptoms and other factors, including depression, anxiety, anger, stress, sleep quality and quantity, self-perceived quality of life and social support, optimism, pessimism and positive affect as well as intimate-partner violence, are assessed online using validated questionnaires (box 1). To assess both acute and persisting symptoms, women are asked to fill in the questionnaires within 1 week following miscarriage or enrolment into a comparison group and 3 and 9 months later. At each timepoint, lifestyle factors, including physical activity, dietary intake, alcohol consumption and smoking, are also assessed. At 3 and 9 months, participants in the miscarriage and abortion groups are asked if they are pregnant again, and if not, whether they are trying to get pregnant.
Box 1. Questionnaires on psychological symptoms and other factors.
Center of Epidemiological Studies Depression Scale (CES-D)—a measure of depressive symptoms within the general population.21
Edinburgh Postnatal Depression Scale (EPDS)—a measure of depressive symptoms during pregnancy and the postnatal period.22
Spielberger State-Trait Anxiety Inventory (STAI)—a measure of anxiety symptoms.23
Brief Screen of Post Traumatic Stress Disorder (SPTSS)—a measure of post-traumatic stress.24
Pittsburgh Sleep Quality Index (PSQI)—a measure of sleep quality.25
The WHO Quality of Life Questionnaire-Brief (WHOQOL-Brief)—a measure of quality of life.26
Social Support Questionnaire—a measure of social support.27
Life Orientation Test-Revised—a measure of optimism and pessimism.28
The Positive and Negative Affect Schedule (PANAS)—a measure of positive affect.29
National Institute for Health and Welfare Domestic Violence Filter and Survey Form.30
Data from medical records and nationwide registries
Patient-reported reproductive background, including any prior pregnancies and their outcome as well as health and medication used at enrolment, will be verified using both national registries and electronic patient records. Information concerning miscarriage and abortion treatment modality (follow-up, medical, surgical) and any treatment-related complications as well as information about subsequent pregnancies while participating in the study are available in hospital records. Hospital records of participants with successful pregnancies will be assessed 3 months after delivery to verify any complications during the pregnancy, at or after delivery as these may affect the 9-month questionnaires.
All participants have consented to linking their data to various Finnish national registries (box 2). Once the study recruitment and follow-up is complete, approvals for the registry linkages will be obtained from the register-keeping authorities. Data from these registers have been validated for research use and provide near-complete follow-up. Registries will be used to access objective data on past and future medical treatment, medical reimbursements, socioeconomic and sociodemographic information, pregnancies and their outcomes as well as death. Of specific interest is the information on diagnosed psychiatric disorders following miscarriage or in comparison groups, which is available in the Care Register for Health Care. The register comprises all psychiatric diagnoses in inpatient or in specialised outpatient care coded according to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10: F00-F99). Psychotropic medication purchases will be retrieved from the Medical Reimbursement Register.
Box 2. National registries.
The Care Register for Health Care.
The Medical Reimbursement Register.
The Incomes Register.
The Population Register.
The Medical Birth Register.
The Register of Congenital Malformations.
The Register of Induced Abortions.
The Causes of Death Register.
Statistics Finland registers.
A voluntary biobank blood sample, including plasma, serum and DNA, is collected as a future resource for studies on biological and genetic basis and risk factors of psychological morbidity to be deposited in the Helsinki Biobank (https://www.helsinginbiopankki.fi/en/front-page) within 1 week after miscarriage or enrolment in a comparison group. We aim to search for endocrine, metabolic, inflammatory and genetic markers involved in miscarriage and psychiatric morbidity.
Statistical analysis
Baseline characteristics of the participants will be summarised using means (SD) for continuous variables and frequencies (percentages) for categorical variables. Differences in psychological symptoms between the miscarriage group and each comparison group (spontaneous ongoing pregnancy, induced abortion, ART) will be analysed at baseline and at the 3-month and 9-month follow-ups, as will within-group differences in changes in symptoms over time, using regression-based methods, including linear, logistic and mixed-effects regression. Regression-based methods will also be used to identify risk factors of symptom severity and persistent symptomatology over time, and to identify factors that foster resilience. To compare psychiatric morbidity between the groups, we may also consider time-to-event analyses, such as Cox regression. Statistical analyses will be performed using statistical software such as R4.6.1 and SPSS32.0.0.0.
Ethics and dissemination
The study will be performed in accordance with ethical principles consistent with the Declaration of Helsinki, ICH/GCPE6 (R2), European Union Clinical Trials Directive and applicable local regulatory requirements. Approval for this study has been obtained from the ethics committee of the Helsinki University Hospital (HUS/3354/2023), and Helsinki University Hospital has given its approval to carry out the study (HUS/617/2023). A collaborative agreement with the Helsinki Biobank has been made for collecting and storing samples of plasma, serum and DNA (BB23-0141). The study is conducted using an electronic platform. Access to the platform requires strong electronic identification. Participants sign an electronic written informed consent on the platform at recruitment. Those depositing a voluntary blood sample in the Biobank sign a separate electronic informed consent with the Biobank prior to blood draw.
The results of this study will be disseminated via publication to peer-reviewed journals.
Footnotes
Funding: This work has been supported by Helsinki University Hospital governed state research funds since 2023 (TYH2026205).Open access funded by Helsinki University Library.
Prepublication history for this paper is available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2026-127865).
Patient consent for publication: Not applicable.
Provenance and peer review: Not commissioned; externally peer reviewed.
Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
References
- 1.Blohm F, Fridén B, Milsom I. A prospective longitudinal population-based study of clinical miscarriage in an urban Swedish population. BJOG. 2008;115:176–82. doi: 10.1111/j.1471-0528.2007.01426.x. [DOI] [PubMed] [Google Scholar]
- 2.Murphy FA, Lipp A, Powles DL. Follow-up for improving psychological well being for women after a miscarriage. Cochrane Database Syst Rev. 2012;2012:CD008679. doi: 10.1002/14651858.CD008679.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Ghosh J, Papadopoulou A, Devall AJ, et al. Methods for managing miscarriage: a network meta-analysis. Cochrane Database Syst Rev. 2021;6:CD012602. doi: 10.1002/14651858.CD012602.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.National Institute for Health and Care Excellence . Ectopic pregnancy and miscarriage: diagnosis and initial management; 2023. NICE Guideline.https://www.nice.org.uk/guidance/ng126 Available. [PubMed] [Google Scholar]
- 5.Filippa S, Jayaweera RT, Blanchard K, et al. Do miscarriage care practice recommendations align with individuals’ needs?: A scoping review. Contraception. 2024;136 doi: 10.1016/j.contraception.2024.110448. [DOI] [PubMed] [Google Scholar]
- 6.Mendes DCG, Fonseca A, Cameirão MS. The relationship between healthcare satisfaction after miscarriage and perinatal grief symptoms: A cross-sectional study on Portugal residents. Soc Sci Med. 2024;353:117037. doi: 10.1016/j.socscimed.2024.117037. [DOI] [PubMed] [Google Scholar]
- 7.Farren J, Jalmbrant M, Falconieri N, et al. Differences in post-traumatic stress, anxiety and depression following miscarriage or ectopic pregnancy between women and their partners: multicenter prospective cohort study. Ultrasound Obstet Gynecol. 2021;57:141–8. doi: 10.1002/uog.23147. [DOI] [PubMed] [Google Scholar]
- 8.Díaz-Pérez E, Haro G, Echeverria I. Psychopathology Present in Women after Miscarriage or Perinatal Loss: A Systematic Review. Psychiatry International . 2023;4:126–35. doi: 10.3390/psychiatryint4020015. [DOI] [Google Scholar]
- 9.Farren J, Jalmbrant M, Falconieri N, et al. Posttraumatic stress, anxiety and depression following miscarriage and ectopic pregnancy: a multicenter, prospective, cohort study. Am J Obstet Gynecol. 2020;222:367. doi: 10.1016/j.ajog.2019.10.102. [DOI] [PubMed] [Google Scholar]
- 10.Quenby S, Gallos ID, Dhillon-Smith RK, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet. 2021;397:1658–67. doi: 10.1016/S0140-6736(21)00682-6. [DOI] [PubMed] [Google Scholar]
- 11.Cheung CS, Chan CH, Ng EH. Stress and anxiety-depression levels following first-trimester miscarriage: a comparison between women who conceived naturally and women who conceived with assisted reproduction. BJOG. 2013;120:1090–7. doi: 10.1111/1471-0528.12251. [DOI] [PubMed] [Google Scholar]
- 12.Volgsten H, Jansson C, Svanberg AS, et al. Longitudinal study of emotional experiences, grief and depressive symptoms in women and men after miscarriage. Midwifery. 2018;64:23–8. doi: 10.1016/j.midw.2018.05.003. [DOI] [PubMed] [Google Scholar]
- 13.Farren J, Mitchell-Jones N, Verbakel JY, et al. The psychological impact of early pregnancy loss. Hum Reprod Update. 2018;24:731–49. doi: 10.1093/humupd/dmy025. [DOI] [PubMed] [Google Scholar]
- 14.Farren J, Jalmbrant M, Falconieri N, et al. Prognostic factors for post-traumatic stress, anxiety and depression in women after early pregnancy loss: a multi-centre prospective cohort study. BMJ Open. 2022;12:e054490. doi: 10.1136/bmjopen-2021-054490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Ip PNP, Ng K, Wan OYK, et al. Cross-sectional study to assess the psychological morbidity of women facing possible miscarriage. Hong Kong Med J. 2023;29:498–505. doi: 10.12809/hkmj219771. [DOI] [PubMed] [Google Scholar]
- 16.Kukulskienė M, Žemaitienė N. Postnatal Depression and Post-Traumatic Stress Risk Following Miscarriage. Int J Environ Res Public Health. 2022;19:6515. doi: 10.3390/ijerph19116515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Hu Y, Tang R, Li X, et al. Spontaneous miscarriage and social support in predicting risks of depression and anxiety: a cohort study in UK Biobank. Am J Obstet Gynecol. 2024;231:655. doi: 10.1016/j.ajog.2024.03.045. [DOI] [PubMed] [Google Scholar]
- 18.Miscarriage . Helsinki: The Finnish Medical Society Duodecim; 2026. Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Gynecological Society.www.kaypahoito.fi Available. [Google Scholar]
- 19.Induced abortion . Helsinki: The Finnish Medical Society Duodecim; 2024. Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Gynecological Society.www.kaypahoito.fi Available. [Google Scholar]
- 20.Ristl R. Sample Size Calculator. https://homepage.univie.ac.at/robin.ristl/samplesize.php?test=proptest n.d. Available.
- 21.Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401. doi: 10.1177/014662167700100306. [DOI] [Google Scholar]
- 22.Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782–6. doi: 10.1192/bjp.150.6.782. [DOI] [PubMed] [Google Scholar]
- 23.Spielberger CD, Gorsuch RL, Lushene RE, et al. Manual for the state-trait anxiety inventory. Palo Alto, CA: Consulting Psychologists Press; 1983. [Google Scholar]
- 24.Carlson EB. Psychometric study of a brief screen for PTSD: assessing the impact of multiple traumatic events. Assessment. 2001;8:431–41. doi: 10.1177/107319110100800408. [DOI] [PubMed] [Google Scholar]
- 25.Buysse DJ, Reynolds CF, III, Monk TH, et al. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193–213. doi: 10.1016/0165-1781(89)90047-4. [DOI] [PubMed] [Google Scholar]
- 26.WHOQOL: measuring quality of life. [12-Dec-2022]. https://www.who.int/tools/whoqol/whoqol-bref Available. Accessed.
- 27.Sarason IG, Sarason BR, Shearin EN, et al. A Brief Measure of Social Support: Practical and Theoretical Implications. J Soc Pers Relat. 1987;4:497–510. doi: 10.1177/0265407587044007. [DOI] [Google Scholar]
- 28.Scheier MF, Carver CS, Bridges MW. Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. J Pers Soc Psychol. 1994;67:1063–78. doi: 10.1037//0022-3514.67.6.1063. [DOI] [PubMed] [Google Scholar]
- 29.Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54:1063–70. doi: 10.1037//0022-3514.54.6.1063. [DOI] [PubMed] [Google Scholar]
- 30.Sherin KM, Sinacore JM, Li XQ, et al. HITS: a short domestic violence screening tool for use in a family practice setting. Fam Med. 1998;30:508–12. [PubMed] [Google Scholar]
